Supporting this, both SCARB1 inhibition and EC-specific Scarb1 KO mitigated TAC-induced heart failure and cardiac fibrosis, identifying SCARB1 on ECs as a pivotal factor in heart failure progression and a potential therapeutic target. This evidence concerns the gene SCARB1 and heart failure.